2024年10月,宜联生物与安进达成合作协议,双方将评估YL201(B7-H3 ADC)和Imdelltra(DLL3/CD3双抗)在SCLC的联合治疗潜力 目前,除上文已经提到的双抗、三抗、ADC及放射性疗法外,包括安进和传奇生物/诺华还押注了相应的CAR-T疗法。 如果您对DLL3 ADC...
2024年10月,宜联生物与安进达成合作协议,双方将评估YL201(B7-H3 ADC)和Imdelltra(DLL3/CD3双抗)在SCLC的联合治疗潜力 目前,除上文已经提到的双抗、三抗、ADC及放射性疗法外,包括安进和传奇生物/诺华还押注了相应的CAR-T疗法。 如果您对DLL3 ADC产品感兴趣,欢迎联系药时代BD团队!我们的邮箱是BD@drugtimes.cn...
2024年10月,宜联生物与安进达成合作协议,双方将评估YL201(B7-H3 ADC)和Imdelltra(DLL3/CD3双抗)在SCLC的联合治疗潜力 目前,除上文已经提到的双抗、三抗、ADC及放射性疗法外,包括安进和传奇生物/诺华还押注了相应的CAR-T疗法。 如果您对DLL3 ADC产品感兴趣,欢迎联系药时代BD团队!我们的邮箱是BD@drugtimes.cn...
Tarlatamab是全球首款靶向DLL3/CD3的双抗产品,也是DLL3赛道中唯一获批上市产品。通过其优异的临床数据,不难看出DLL3的确是个值得下注的靶点。 目前,全球范围内进入II期及以上临床阶段的DLL3产品几乎均为双抗/三抗产品。除已上市其中包括BI的BI 764532(DLL3/CD3双抗)、苏州泽璟制药的ZG-006(CD3/DLL3/DLL3三...
on tumor cells and CD3 on T cells, they create an immunological synapse, with the goal of activating T cells. Once the T cells are activated, they create perforin pores in the tumor cell membrane, allowing for the transfer of granzymes, which may induce apoptosis of the tumor cell. Activa...
近年来,针对DLL3靶点的临床研究已经初步证明该靶点在癌症治疗上的潜力。目前,全球针对该靶点的研发管线有13条(如有遗漏,欢迎补充),药物类型包括单抗、双抗、ADC和CAR-T,其中双抗候选药物的靶点主要集中在CD3×DLL3上。13款候选药物的适...
Bispecific antibody constructs binding dll3 and cd3. Google Patents; 2021. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in previously treated HER2-Positive breast Cancer. N Engl J Med. 2020;382:610–21. Article CAS PubMed Google Scholar ...
The Neon™ NxT electroporation system was employed to transfect circRNA into human CD3 + T cells. We first investigated the expression efficiency of circRNA under different voltages (1400V, 1600V, and 1800V). After electroporating T cells with EGFP-encoding circRNA, the 1400V condition vi...
et al. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 18(24), 2639–2649 (2022). Article PubMed CAS Google Scholar Furuta, M. et al. DLL3 regulates the migration and invasion of...
The Neon™ NxT electroporation system was employed to transfect circRNA into human CD3 + T cells. We first investigated the expression efficiency of circRNA under different voltages (1400V, 1600V, and 1800V). After electroporating T cells with EGFP-encoding circRNA, the 1400V condition vi...